LB PharmaceuticalsCommon Stock EBIT

LB PharmaceuticalsCommon Stock posts a EBIT of $-93M as of June 2026. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a EBIT near $110B is typical. LB PharmaceuticalsCommon Stock's $-93M is lower that level. That is roughly 100.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of LB PharmaceuticalsCommon Stock's financial statement story. At $-93M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LBRX's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; LB PharmaceuticalsCommon Stock's other metric pages and overview cover the third.

Judging LB PharmaceuticalsCommon Stock against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in EBIT easier to interpret. Start with $-93M here, then scan peer and history charts to see if the gap is persistent.